]>
IRCT2017052834184N1 IRCT 2017-08-07 vice chancellor of research Shiraz University of Medical Sciences comparison between pregnancy outcome of in vitro fertilization (assisted reproductive technology ) with and without Gonadotropin-releasing hormone agonist Frozen Thawed Embryo Transfer Cycles: A Comparison of Pregnancy Outcomes with and without Prior Pituitary Suppression by Gonadotropin-releasing hormone Agonists 2012-11-01 anticipated 200 Complete https://irct.ir/trial/26188 interventional Randomization: Randomized, Blinding: Not blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment. 2 Condition 1: in vitro fertilization. Condition 2: infertility. Intervention 1: Participanpatients in group A received GnRH agonist prior to ovulation induction.0.5 mg of Busereline acetate (a GnRH agonist) (Suprefact, Hoechst AG, Germany) was injected subcutaneously daily starting on the 21st day of menstrual cycle (mid luteal phase). On the first day of menstruation, GnRH agonist dose was reduced to 0.3 mg SC per day. Intervention 2: patients in group B had steroid manipulation and routine IVF regimen without prior down-regulation of the pituitary.
public Zohre Chitsazi
Ob/Gyn department office, Shahid Faghihi Hospital,Zand St
Shiraz Iran (Islamic Republic of) +98 917 714 4835 z.chitsazi@yahoo.com Shiraz University of Medical Sciences scientific Zohre Chitsazi
Ob/Gyn department office, Shahid Faghihi hospital,,Zand st
Shiraz Iran (Islamic Republic of) +98 917 714 4835 z.chitsazi@yahoo.com Shiraz University of Medical Sciences Iran (Islamic Republic of) inclusion criteria: Documented infertility of any cause;Aged 20-39 years; Couples undergoing ART with their own gametes;Women stimulated with a long GnRH agonist protocol of IVF (for group A);Couples having frozen embryo available for transfer exclusion criteria: Age > 39 years; High grade endometriosis;Existence of myoma or adhesion in uterus;Body mass index (BMI) more than 29 kg/m2 or less than 18 kg/m2;Oocyte donation cycles 20 years 39 years Female Z31.2 N97 Admission for harvesting or implantation of ova inability to achieve a pregnancy Treatment - Drugs Treatment - Drugs Participanpatients in group A received GnRH agonist prior to ovulation induction.0.5 mg of Busereline acetate (a GnRH agonist) (Suprefact, Hoechst AG, Germany) was injected subcutaneously daily starting on the 21st day of menstrual cycle (mid luteal phase). On the first day of menstruation, GnRH agonist dose was reduced to 0.3 mg SC per day. patients in group B had steroid manipulation and routine IVF regimen without prior down-regulation of the pituitary Pregnancy outcome. Timepoint: since 16 days post transfer until delivery. Method of measurement: beta hCG, Ultrasound. Clinical pregnancy. Timepoint: 5 weeks after transfer date. Method of measurement: observation of intrauterine gestational sac during ultrasound examination 5 weeks after transfer date. Chemical pregnancy. Timepoint: 16 days following thawed embryo transfer. Method of measurement: Serum βHCG level > 10 IU per L. Ongoing pregnancy. Timepoint: 12 weeks after transfer date. Method of measurement: presence of intrauterine fetal heart motion. Implantation rate. Timepoint: 9 weeks post transfer. Method of measurement: number of gestational sacs with fetal pole detected using vaginal ultrasound to the number of transferred embryos. Miscarriage rate. Timepoint: under the 20th week of gestation. Method of measurement: ultrasound and beta hCG. vice chancellor of research Shiraz University of Medical Sciences Approved 2010-08-20 Ethical Committee of Shiraz University of Medical Sciences Shiraz University of Medical Sciences, Zand ST, Shiraz Iran (Islamic Republic of)